Community Practice Connections™: Medical Crossfire®: Foundations in Outpatient Administration of Infused Therapies for COVID-19: Keeping Patients Out of the Hospital

Release Date: April 26, 2021
Expiration Date: April 26, 2022

Activity Overview

COVID-19 is a rapidly evolving global public health threat that has affected virtually all aspects of patient care, including the treatment of patients with other acute and chronic diseases. The cause of COVID-19 is SARS-CoV-2, a β-coronavirus. Recent research efforts have focused on the development of vaccines, new antiviral agents, convalescent plasma infusions, and monoclonal antibodies for either the prevention or treatment of COVID-19. Neutralizing monoclonal antibodies to SARS-CoV-2 have the potential for both therapeutic and prophylactic applications. Neutralizing monoclonal antibodies directed against SARS-CoV-2 have been developed and are under investigation in clinical trials. In addition, several of these drugs have recently been approved by the United States Food and Drug Administration (FDA) and drugs made available under FDA emergency use authorization (EUA).

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the Medical Crossfire^®: Foundations in Outpatient Administration of Infused Therapies for COVID-19: Keeping Patients out of the Hospital held in February and March 2021. This unique and engaging multi-media activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with SARS-CoV-2 infection, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This educational activity is supported by an educational grant from Lilly.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com

Target Audience

Physicians, nurses, and pharmacists who specialize in administering infused therapies in an outpatient setting are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Discuss best practices for administration of infused therapies in patients with confirmed COVID-19 infection at elevated risk of hospitalization
• Identify signs and symptoms of potential adverse reactions to infused neutralizing antibody therapy in patients with confirmed with COVID-19 infection
• Incorporate best practices for patient counseling and education regarding the administration of infused therapies in patients with confirmed COVID-19 infection

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.

Faculty

Disclosures: Grant/Research Support: Regeneron Pharmaceuticals (research grants to the institution), Hoffmann-La Roche.

Disclosures: Other: Research advisor for Kedrion Biopharma (rabies immunoglobulin research)

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.